Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
Variants in the genome interact with each other and with the environment to affect risk of cardiovascular disease
Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare system and Copenhagen University, published a study today in the journal Cell titled “Complex effects of sequence variants on lipid levels and coronary artery disease”. The work described in the paper is based on searching for variants in the genome that are associated with variance in quantitative traits and the assumption that those variants must interact either with other variants or components of the environment.
deCODE genetics and its collaborators employed AI to develop a protein score to predict major atherosclerotic cardiovascular disease events
Award by the American Society of Human Genetics
At its Annual meeting in October 2017 in Orlando, the American Society of Human Genetics (ASHG), presented Dr. Kári Stefánsson, founder and CEO of deCODE genetics, with the William Allan Award. The award, the top prize given by the society, recognizes a scientist for substantial and far-reaching scientific contributions to human genetics. The ASHG has distributed video footage from the award ceremony. The introduction is given by Professor Mark Daly of Harvard University.